Ascend Capital’s Avanos Medical AVNS Stock Holding History

Ascend Capital’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-127,741	Closed	-$5.01M	–	166
2017 Q2	$5.01M	Buy	+127,741	New	+$4.83M	0.23%	110

Other funds holding AVNS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ascend Capital's AVNS Position: Q3 2017 in Review

Ascend Capital sold out of Avanos Medical (AVNS) in Q3 2017, closing a stake of 127,741 shares — an estimated $5.01M sold.

Ascend Capital first reported a position in AVNS in Q2 2017 and held it in 1 quarter. The position peaked at $5.01M in Q2 2017. 318 funds tracked by Wall St. Rank hold AVNS as of Q3 2017.

Ascend Capital reported no remaining Avanos Medical position as of Q3 2017 after selling out during the quarter.
Ascend Capital sold 127,741 Avanos Medical shares in Q3 2017, an estimated $5.01M.
Ascend Capital first reported a position in Avanos Medical in Q2 2017 and held it in 1 quarter.
Ascend Capital's Avanos Medical position peaked at $5.01M in Q2 2017.
318 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2017.

Based on Ascend Capital's 13F filing for Q3 2017, filed 13 Nov 2017.